




SUPPLEMENTARY FIGURES




eFigure 1: STARD diagram of participants. 242 participants were recruited to the study. Following initial analysis for variants known to cause mitochondrial disease and individual searches for mitochondrial disease mimics, 57 patients were found to have nuclear DNA variants and 73 patients were found to have mitochondrial DNA variants that could explain their disease. Of the 57 patients with nuclear DNA variants, 7 had variants in genes not associated with mitochondrial disease, but with phenotypes that mimic mitochondrial disease. Of the 112 participants remaining without a diagnosis, 11 were found to have variants of uncertain significance in genes known to cause mitochondrial disease that required functional genetic confirmation and 101 participants had no candidate genetic diagnosis and required further investigation.



eFigure 2: Long-range polymerase chain reaction amplification of single deletions in mitochondrial DNA from blood versus urine. A single amplicon amplification of mitochondrial DNA from blood showed no single deletions in three chronic progressive external ophthalmoplegia (CPEO) patients (left panel; blue arrow indicates full-length mitochondrial DNA at 16.5kb). D8 and B5 had nuclear mutations identified by whole genome sequencing (WGS) associated with CPEO but no mitochondrial DNA deletion in blood. Whereas B34 had a single deletion in mitochondrial DNA associated with chronic progressive external ophthalmoplegia that was not detected by WGS in blood. When comparing to urine (right panel), single deletions were observed for all three patients (orange arrows; blue arrow indicates full-length mitochondrial DNA at 16.5kb), confirming the absence of deletions in blood not the inability of WGS to detect deletions in blood.



eFigure 3: Clinical classification of mitochondrial disease criteria and number of molecular diagnoses. (A) The percentage of patients diagnosed by whole genome sequencing for each of the Nijmegen criteria, showing that a diagnosis by WGS is not determined by Nijmegen criteria classification (error bars = 95% confidence intervals). (B) The number of patients diagnosed by WGS compared to patient age at presentation. Patients <50 years old were more likely to obtain a diagnosis by WGS compared to those >50 years old. Blue denotes diagnosed by WGS, red denotes undiagnosed after WGS.



eFigure 4: Altered splicing in congenital myasthenic patient-derived fibroblasts with a homozygous c.358+3G>T variant. (A) Polymerase chain reaction amplification of *MUSK* exons 1 to 4 and exons 2 to 5 of cDNA from cycloheximide-treated patient fibroblasts showed wild type (orange arrowhead) and variant transcripts (blue arrowhead) for the patient only. (B) Sequencing of cDNA confirmed normal splicing out of intron 3 from wild type transcripts (solid line) with intronic read-through of 44 base pairs (blue exon 3 extension) to an alternate donor splice site (red dot and green arrow) before splicing out of the remaining intron 3 in the variant transcripts (dotted line). Possible alternate donor splice sites are shown as red dots along the intron. (C) The *MUSK* c.358+3G>T variant abolishes the existing splice site (transition from orange to blue text), causing read-through into the intron (blue nucleotide sequence) for 44 base pairs to an alternate donor splice site (red dot and green arrow). The intronic read-through would result in a coding frameshift, introduction of a serine residue, before premature termination of translation at a stop codon (*) created by the c.358+3T variant.

SUPPLEMENTARY TABLES

eTable 1: Positive controls used to assess the capability of WGS to identify known variants in nDNA and mtDNA extracted from blood or autopsy samples

Sample #	Age	Sex	Gene	Mode	Nucleotide and amino acid change
1	26	F	<i>POLG</i>	AR	c.2551A>G p.T851A
				AR	c.487C>T; p.P163S
2	61	F	<i>POLG</i>	AR	c.1760C>T; p.Pro587Leu: in cis c.752C>T; p.Thr251Ile
3	65	M	<i>POLG</i>	AR	c.1760C>T; p.Pro587Leu: in cis c.752C>T; p.Thr251Ile
4	49	F	<i>POLG</i>	AR	c.2551A>G; p.Thr851Ala
				AR	c.1402A>G; p.Asn468Asp
5	40	F	<i>POLG</i>	AR	c.1399G>A; p.Ala467Thr
6	54	F	<i>POLG</i>	AR	c.1684C>T; p.Arg562Trp
				AR	c.1399G>A; p.Ala467Thr
7	26	F	<i>POLG</i>	AR	c.2243G>C; p.Trp748Ser
				AR	c.1399G>A; p.Ala467Thr
8	43	M	<i>TYMP</i>	AR	c.1228_1247delGACGGCCCCCGCGCTCAGCGG; p.Asp410Profs?
9	30	M	<i>TYMP</i>	AR	c.1228_1247delGACGGCCCCCGCGCTCAGCGG; p.Asp410Profs?
10	24	F	<i>TYMP</i>	AR	c.931G>T; p.Gly311Cys
				AR	c.1311delG; p.Trp437Cysfs?
11	31	F	<i>WFS1</i>	AR	c.1243_1245delGTC; p.Val415del
				AR	c.2100G>T, p.Trp700Cys
12	25	F	<i>YARS2</i>	AR	c.156C>G; p.Phe52Leu
13	39	F	<i>TWNK</i>	AD	c.1106C>A; p.Ser369Tyr
14	62	F	<i>TWNK</i>	AD	c.1106C>A; p.Ser369Tyr
15	23	F	<i>OPA1</i>	AD	c.1334G>A; p.Arg445His
16	54	F	<i>OPA1</i>	AD	c.1334G>A; p.Arg445His
17	74	F	<i>OPA1</i>	AD	c.1313A>G; p.Asp438Gly
18	44	F	<i>OPA1</i>	AD	c.1313A>G; p.Asp438Gly
19	14	M	<i>OPA1</i>	AD	c.655C>T; p.Gln219Ter
20	53	F	<i>OPA1</i>	AD	c.655C>T; p.Gln219Ter
21	40	M	<i>OPA1</i>	AD	c.1325A>G; p.Asp442Gly

22	61	F	OPA1	AD	c.1325A>G; p.Asp442Gly
23	67	M	OPA1	AD	c.888T>A; p.Asp296Glu
24	72	F	OPA1	AD	c.888T>A; p.Asp296Glu
25	70	F	OPA1	AD	c.888T>A; p.Asp296Glu
26	41	F	OPA1	AD	c.888T>A; p.Asp296Glu
27	42	F	OPA1	AD	c.888T>A; p.Asp296Glu
28	41	F	OPA1	AD	c.888T>A; p.Asp296Glu
29	39	M	OPA1	AD	c.888T>A; p.Asp296Glu
30	69	F	OPA1	AD	c.888T>A; p.Asp296Glu
31	64	M	MT-RNR1	Mat	m.1555A>G
32	47	F	MT-TL1	Mat	m.3243A>G
33	16	M	MT-TL1	Mat	m.3243A>G
34	12	F	MT-TL1	Mat	m.3243A>G
35	51	M	MT-TL1	Mat	m.3243A>G
36	38	F	MT-TL1	Mat	m.3243A>G
37	53	F	MT-TL1	Mat	m.3243A>G
38	45	M	MT-TL1	Mat	m.3243A>G
39	57	F	MT-TL1	Mat	m.3302A>G
40	23	F	MT-ND1	Mat	m.3460G>A; p.Ala52Thr
41	20	F	MT-TK	Mat	m.8344A>G
42	27	M	Single deletion ^M	Spo	4.8kb single deletion

Sample # = Positive control sample identification number for this study; F = Female; M = Male; Mode = Mode of inheritance; AD = Autosomal Dominant; AR = Autosomal Recessive; Mat = Maternal; Spo = Sporadic. ter? = downstream termination site not able to be predicted. ^MAll samples were blood DNA except for Sample #42, which was from muscle obtained at autopsy.

eTable 2: Curated Mitochondrial Disease Nuclear Gene Panel Generated from Literature Review

Autosomal Dominant	Autosomal Recessive	X-Linked
AARS2;AFG3L2;ATAD3A; CHCHD10;CYCS;DNA2;DNM1L; HSPD1;MFN2;OPA1;OPA3; POLG;POLG2;RRM2B;SDHAF2; SDHB;SDHC;SDHD;SLC25A4; STXBP1;TWNK	AARS2;ABAT;ACAD9;ACSM2A;ACSM5;ADCK3;AFG3L2;AGK;ALDH1L1;ANO10;APOA1BP;APOPT1;APTX;ARHGEF5;ATAD3A;ATP5A1;ATP5E;ATPAF2;BCKDHB;BCS1L;BOLA3; C12orf65;CARS2;CEP89;CISD2;CLPB;CLPP;COA3;COA5;COA6;COA7;COQ2;COQ4;COQ6;COQ9;COX4I2;COX6A1;COX6B1;COX8A;COX10;COX14;COX15;COX20;CYC1;DARS2; DGUOK;DLAT;DLD;DNAJC19;DNM1L;EARS2;ECHS1;ELAC2;ERCC6L2;ETFA;ETFDH;ETHE1;FAAH2;FARS2;FASN;FASTKD2;FBXL4;FDX1L;FH;FLAD1;FNDC1;FOXRED1;FXN; GARS;GFER;GFM1;GFM2;GLRX5;GPT2;GTPBP3;HARS2;HERC2;HIBCH;HKDC1;HSPD1;HTRA2;IARS2;IBA57;IREB2;ISCA2;ISCU;KARS;LARS2;LIA8;LIP71;LONP1;LRPPRC; LYRM4;LYRM7;MAGI1;MARS2;MECR;MEF2A;METAP1D;MFF;MFN2;MGME1;MICU1;MIEP;MPC1;MPV17;MRPL3;MRPL12;MRPL44;MRPS7;MRPS16;MRPS22;MRPS23;MTFMT; MT01;MTPAP;NARS2;NAXE;NDR63;NDUFA2;NDUFA4;NDUFA9;NDUFA10;NDUFA11;NDUFA12;NDUFA13;NDUFAF1;NDUFAF2;NDUFAF3;NDUFAF4;NDUFAF5;NDUFAF6; NDUFB3;NDUFB8;NDUFB9;NDUFS1;NDUFS2;NDUFS3;NDUFS4;NDUFS6;NDUFS7;NDUFS8;NDUFS11;NDUFS12;NDUFS13;NDUFS14;NDUFS15;NDUFS16;NDUFS17;NDUFS18;NDUFS19;NDUFS20;NDUFS21;NDUFS22;NDUFS23;NDUFS24;NDUFS25;NDUFS26;NDUFS27;NDUFS28;NDUFS29;NDUFS30;NDUFS31;NDUFS32;NDUFS33;NDUFS34;NDUFS35;NDUFS36;NDUFS37;NDUFS38;NDUFS39;NDUFS40;NDUFS41;NDUFS42;NDUFS43;NDUFS44;NDUFS45;NDUFS46;NDUFS47;NDUFS48;NDUFS49;NDUFS50;NDUFS51;NDUFS52;NDUFS53;NDUFS54;NDUFS55;NDUFS56;NDUFS57;NDUFS58;NDUFS59;NDUFS60;NDUFS61;NDUFS62;NDUFS63;NDUFS64;NDUFS65;NDUFS66;NDUFS67;NDUFS68;NDUFS69;NDUFS70;NDUFS71;NDUFS72;NDUFS73;NDUFS74;NDUFS75;NDUFS76;NDUFS77;NDUFS78;NDUFS79;NDUFS80;NDUFS81;NDUFS82;NDUFS83;NDUFS84;NDUFS85;NDUFS86;NDUFS87;NDUFS88;NDUFS89;NDUFS90;NDUFS91;NDUFS92;NDUFS93;NDUFS94;NDUFS95;NDUFS96;NDUFS97;NDUFS98;NDUFS99;NDUFS100;NDUFS101;NDUFS102;NDUFS103;NDUFS104;NDUFS105;NDUFS106;NDUFS107;NDUFS108;NDUFS109;NDUFS110;NDUFS111;NDUFS112;NDUFS113;NDUFS114;NDUFS115;NDUFS116;NDUFS117;NDUFS118;NDUFS119;NDUFS120;NDUFS121;NDUFS122;NDUFS123;NDUFS124;NDUFS125;NDUFS126;NDUFS127;NDUFS128;NDUFS129;NDUFS130;NDUFS131;NDUFS132;NDUFS133;NDUFS134;NDUFS135;NDUFS136;NDUFS137;NDUFS138;NDUFS139;NDUFS140;NDUFS141;NDUFS142;NDUFS143;NDUFS144;NDUFS145;NDUFS146;NDUFS147;NDUFS148;NDUFS149;NDUFS150;NDUFS151;NDUFS152;NDUFS153;NDUFS154;NDUFS155;NDUFS156;NDUFS157;NDUFS158;NDUFS159;NDUFS160;NDUFS161;NDUFS162;NDUFS163;NDUFS164;NDUFS165;NDUFS166;NDUFS167;NDUFS168;NDUFS169;NDUFS170;NDUFS171;NDUFS172;NDUFS173;NDUFS174;NDUFS175;NDUFS176;NDUFS177;NDUFS178;NDUFS179;NDUFS180;NDUFS181;NDUFS182;NDUFS183;NDUFS184;NDUFS185;NDUFS186;NDUFS187;NDUFS188;NDUFS189;NDUFS190;NDUFS191;NDUFS192;NDUFS193;NDUFS194;NDUFS195;NDUFS196;NDUFS197;NDUFS198;NDUFS199;NDUFS200;NDUFS201;NDUFS202;NDUFS203;NDUFS204;NDUFS205;NDUFS206;NDUFS207;NDUFS208;NDUFS209;NDUFS210;NDUFS211;NDUFS212;NDUFS213;NDUFS214;NDUFS215;NDUFS216;NDUFS217;NDUFS218;NDUFS219;NDUFS220;NDUFS221;NDUFS222;NDUFS223;NDUFS224;NDUFS225;NDUFS226;NDUFS227;NDUFS228;NDUFS229;NDUFS230;NDUFS231;NDUFS232;NDUFS233;NDUFS234;NDUFS235;NDUFS236;NDUFS237;NDUFS238;NDUFS239;NDUFS240;NDUFS241;NDUFS242;NDUFS243;NDUFS244;NDUFS245;NDUFS246;NDUFS247;NDUFS248;NDUFS249;NDUFS250;NDUFS251;NDUFS252;NDUFS253;NDUFS254;NDUFS255;NDUFS256;NDUFS257;NDUFS258;NDUFS259;NDUFS260;NDUFS261;NDUFS262;NDUFS263;NDUFS264;NDUFS265;NDUFS266;NDUFS267;NDUFS268;NDUFS269;NDUFS270;NDUFS271;NDUFS272;NDUFS273;NDUFS274;NDUFS275;NDUFS276;NDUFS277;NDUFS278;NDUFS279;NDUFS280;NDUFS281;NDUFS282;NDUFS283;NDUFS284;NDUFS285;NDUFS286;NDUFS287;NDUFS288;NDUFS289;NDUFS290;NDUFS291;NDUFS292;NDUFS293;NDUFS294;NDUFS295;NDUFS296;NDUFS297;NDUFS298;NDUFS299;NDUFS300;NDUFS301;NDUFS302;NDUFS303;NDUFS304;NDUFS305;NDUFS306;NDUFS307;NDUFS308;NDUFS309;NDUFS310;NDUFS311;NDUFS312;NDUFS313;NDUFS314;NDUFS315;NDUFS316;NDUFS317;NDUFS318;NDUFS319;NDUFS320;NDUFS321;NDUFS322;NDUFS323;NDUFS324;NDUFS325;NDUFS326;NDUFS327;NDUFS328;NDUFS329;NDUFS330;NDUFS331;NDUFS332;NDUFS333;NDUFS334;NDUFS335;NDUFS336;NDUFS337;NDUFS338;NDUFS339;NDUFS340;NDUFS341;NDUFS342;NDUFS343;NDUFS344;NDUFS345;NDUFS346;NDUFS347;NDUFS348;NDUFS349;NDUFS350;NDUFS351;NDUFS352;NDUFS353;NDUFS354;NDUFS355;NDUFS356;NDUFS357;NDUFS358;NDUFS359;NDUFS360;NDUFS361;NDUFS362;NDUFS363;NDUFS364;NDUFS365;NDUFS366;NDUFS367;NDUFS368;NDUFS369;NDUFS370;NDUFS371;NDUFS372;NDUFS373;NDUFS374;NDUFS375;NDUFS376;NDUFS377;NDUFS378;NDUFS379;NDUFS380;NDUFS381;NDUFS382;NDUFS383;NDUFS384;NDUFS385;NDUFS386;NDUFS387;NDUFS388;NDUFS389;NDUFS390;NDUFS391;NDUFS392;NDUFS393;NDUFS394;NDUFS395;NDUFS396;NDUFS397;NDUFS398;NDUFS399;NDUFS400;NDUFS401;NDUFS402;NDUFS403;NDUFS404;NDUFS405;NDUFS406;NDUFS407;NDUFS408;NDUFS409;NDUFS410;NDUFS411;NDUFS412;NDUFS413;NDUFS414;NDUFS415;NDUFS416;NDUFS417;NDUFS418;NDUFS419;NDUFS420;NDUFS421;NDUFS422;NDUFS423;NDUFS424;NDUFS425;NDUFS426;NDUFS427;NDUFS428;NDUFS429;NDUFS430;NDUFS431;NDUFS432;NDUFS433;NDUFS434;NDUFS435;NDUFS436;NDUFS437;NDUFS438;NDUFS439;NDUFS440;NDUFS441;NDUFS442;NDUFS443;NDUFS444;NDUFS445;NDUFS446;NDUFS447;NDUFS448;NDUFS449;NDUFS450;NDUFS451;NDUFS452;NDUFS453;NDUFS454;NDUFS455;NDUFS456;NDUFS457;NDUFS458;NDUFS459;NDUFS460;NDUFS461;NDUFS462;NDUFS463;NDUFS464;NDUFS465;NDUFS466;NDUFS467;NDUFS468;NDUFS469;NDUFS470;NDUFS471;NDUFS472;NDUFS473;NDUFS474;NDUFS475;NDUFS476;NDUFS477;NDUFS478;NDUFS479;NDUFS480;NDUFS481;NDUFS482;NDUFS483;NDUFS484;NDUFS485;NDUFS486;NDUFS487;NDUFS488;NDUFS489;NDUFS490;NDUFS491;NDUFS492;NDUFS493;NDUFS494;NDUFS495;NDUFS496;NDUFS497;NDUFS498;NDUFS499;NDUFS500;NDUFS501;NDUFS502;NDUFS503;NDUFS504;NDUFS505;NDUFS506;NDUFS507;NDUFS508;NDUFS509;NDUFS510;NDUFS511;NDUFS512;NDUFS513;NDUFS514;NDUFS515;NDUFS516;NDUFS517;NDUFS518;NDUFS519;NDUFS520;NDUFS521;NDUFS522;NDUFS523;NDUFS524;NDUFS525;NDUFS526;NDUFS527;NDUFS528;NDUFS529;NDUFS530;NDUFS531;NDUFS532;NDUFS533;NDUFS534;NDUFS535;NDUFS536;NDUFS537;NDUFS538;NDUFS539;NDUFS540;NDUFS541;NDUFS542;NDUFS543;NDUFS544;NDUFS545;NDUFS546;NDUFS547;NDUFS548;NDUFS549;NDUFS550;NDUFS551;NDUFS552;NDUFS553;NDUFS554;NDUFS555;NDUFS556;NDUFS557;NDUFS558;NDUFS559;NDUFS560;NDUFS561;NDUFS562;NDUFS563;NDUFS564;NDUFS565;NDUFS566;NDUFS567;NDUFS568;NDUFS569;NDUFS570;NDUFS571;NDUFS572;NDUFS573;NDUFS574;NDUFS575;NDUFS576;NDUFS577;NDUFS578;NDUFS579;NDUFS580;NDUFS581;NDUFS582;NDUFS583;NDUFS584;NDUFS585;NDUFS586;NDUFS587;NDUFS588;NDUFS589;NDUFS589;NDUFS590;NDUFS591;NDUFS592;NDUFS593;NDUFS594;NDUFS595;NDUFS596;NDUFS597;NDUFS598;NDUFS599;NDUFS600;NDUFS601;NDUFS602;NDUFS603;NDUFS604;NDUFS605;NDUFS606;NDUFS607;NDUFS608;NDUFS609;NDUFS610;NDUFS611;NDUFS612;NDUFS613;NDUFS614;NDUFS615;NDUFS616;NDUFS617;NDUFS618;NDUFS619;NDUFS620;NDUFS621;NDUFS622;NDUFS623;NDUFS624;NDUFS625;NDUFS626;NDUFS627;NDUFS628;NDUFS629;NDUFS630;NDUFS631;NDUFS632;NDUFS633;NDUFS634;NDUFS635;NDUFS636;NDUFS637;NDUFS638;NDUFS639;NDUFS640;NDUFS641;NDUFS642;NDUFS643;NDUFS644;NDUFS645;NDUFS646;NDUFS647;NDUFS648;NDUFS649;NDUFS650;NDUFS651;NDUFS652;NDUFS653;NDUFS654;NDUFS655;NDUFS656;NDUFS657;NDUFS658;NDUFS659;NDUFS660;NDUFS661;NDUFS662;NDUFS663;NDUFS664;NDUFS665;NDUFS666;NDUFS667;NDUFS668;NDUFS669;NDUFS669;NDUFS670;NDUFS671;NDUFS672;NDUFS673;NDUFS674;NDUFS675;NDUFS676;NDUFS677;NDUFS678;NDUFS679;NDUFS679;NDUFS680;NDUFS681;NDUFS682;NDUFS683;NDUFS684;NDUFS685;NDUFS686;NDUFS687;NDUFS688;NDUFS689;NDUFS689;NDUFS690;NDUFS691;NDUFS692;NDUFS693;NDUFS694;NDUFS695;NDUFS696;NDUFS697;NDUFS698;NDUFS699;NDUFS699;NDUFS700;NDUFS701;NDUFS702;NDUFS703;NDUFS704;NDUFS705;NDUFS706;NDUFS707;NDUFS708;NDUFS709;NDUFS709;NDUFS710;NDUFS711;NDUFS712;NDUFS713;NDUFS714;NDUFS715;NDUFS716;NDUFS717;NDUFS718;NDUFS719;NDUFS719;NDUFS720;NDUFS721;NDUFS722;NDUFS723;NDUFS724;NDUFS725;NDUFS726;NDUFS727;NDUFS728;NDUFS729;NDUFS729;NDUFS730;NDUFS731;NDUFS732;NDUFS733;NDUFS734;NDUFS735;NDUFS736;NDUFS737;NDUFS738;NDUFS739;NDUFS739;NDUFS740;NDUFS741;NDUFS742;NDUFS743;NDUFS744;NDUFS745;NDUFS746;NDUFS747;NDUFS748;NDUFS749;NDUFS749;NDUFS750;NDUFS751;NDUFS752;NDUFS753;NDUFS754;NDUFS755;NDUFS756;NDUFS757;NDUFS758;NDUFS759;NDUFS759;NDUFS760;NDUFS761;NDUFS762;NDUFS763;NDUFS764;NDUFS765;NDUFS766;NDUFS767;NDUFS768;NDUFS769;NDUFS769;NDUFS770;NDUFS771;NDUFS772;NDUFS773;NDUFS774;NDUFS775;NDUFS776;NDUFS777;NDUFS778;NDUFS779;NDUFS779;NDUFS780;NDUFS781;NDUFS782;NDUFS783;NDUFS784;NDUFS785;NDUFS786;NDUFS787;NDUFS788;NDUFS789;NDUFS789;NDUFS790;NDUFS791;NDUFS792;NDUFS793;NDUFS794;NDUFS795;NDUFS796;NDUFS797;NDUFS798;NDUFS799;NDUFS799;NDUFS800;NDUFS801;NDUFS802;NDUFS803;NDUFS804;NDUFS805;NDUFS806;NDUFS807;NDUFS808;NDUFS809;NDUFS809;NDUFS810;NDUFS811;NDUFS812;NDUFS813;NDUFS814;NDUFS815;NDUFS816;NDUFS817;NDUFS818;NDUFS819;NDUFS819;NDUFS820;NDUFS821;NDUFS822;NDUFS823;NDUFS824;NDUFS825;NDUFS826;NDUFS827;NDUFS828;NDUFS829;NDUFS829;NDUFS830;NDUFS831;NDUFS832;NDUFS833;NDUFS834;NDUFS835;NDUFS836;NDUFS837;NDUFS838;NDUFS839;NDUFS839;NDUFS840;NDUFS841;NDUFS842;NDUFS843;NDUFS844;NDUFS845;NDUFS846;NDUFS847;NDUFS848;NDUFS849;NDUFS849;NDUFS850;NDUFS851;NDUFS852;NDUFS853;NDUFS854;NDUFS855;NDUFS856;NDUFS857;NDUFS858;NDUFS859;NDUFS859;NDUFS860;NDUFS861;NDUFS862;NDUFS863;NDUFS864;NDUFS865;NDUFS866;NDUFS867;NDUFS868;NDUFS869;NDUFS869;NDUFS870;NDUFS871;NDUFS872;NDUFS873;NDUFS874;NDUFS875;NDUFS876;NDUFS877;NDUFS878;NDUFS879;NDUFS879;NDUFS880;NDUFS881;NDUFS882;NDUFS883;NDUFS884;NDUFS885;NDUFS886;NDUFS887;NDUFS888;NDUFS889;NDUFS889;NDUFS890;NDUFS891;NDUFS892;NDUFS893;NDUFS894;NDUFS895;NDUFS896;NDUFS897;NDUFS898;NDUFS899;NDUFS899;NDUFS900;NDUFS901;NDUFS902;NDUFS903;NDUFS904;NDUFS905;NDUFS906;NDUFS907;NDUFS908;NDUFS909;NDUFS909;NDUFS910;NDUFS911;NDUFS912;NDUFS913;NDUFS914;NDUFS915;NDUFS916;NDUFS917;NDUFS918;NDUFS919;NDUFS919;NDUFS920;NDUFS921;NDUFS922;NDUFS923;NDUFS924;NDUFS925;NDUFS926;NDUFS927;NDUFS928;NDUFS929;NDUFS929;NDUFS930;NDUFS931;NDUFS932;NDUFS933;NDUFS934;NDUFS935;NDUFS936;NDUFS937;NDUFS938;NDUFS939;NDUFS939;NDUFS940;NDUFS941;NDUFS942;NDUFS943;NDUFS944;NDUFS945;NDUFS946;NDUFS947;NDUFS948;NDUFS949;NDUFS949;NDUFS950;NDUFS951;NDUFS952;NDUFS953;NDUFS954;NDUFS955;NDUFS956;NDUFS957;NDUFS958;NDUFS959;NDUFS959;NDUFS960;NDUFS961;NDUFS962;NDUFS963;NDUFS964;NDUFS965;NDUFS966;NDUFS967;NDUFS968;NDUFS969;NDUFS969;NDUFS970;NDUFS971;NDUFS972;NDUFS973;NDUFS974;NDUFS975;NDUFS976;NDUFS977;NDUFS978;NDUFS979;NDUFS979;NDUFS980;NDUFS981;NDUFS982;NDUFS983;NDUFS984;NDUFS985;NDUFS986;NDUFS987;NDUFS988;NDUFS989;NDUFS989;NDUFS990;NDUFS991;NDUFS992;NDUFS993;NDUFS994;NDUFS995;NDUFS996;NDUFS997;NDUFS998;NDUFS999;NDUFS999;NDUFS1000;NDUFS1001;NDUFS1002;NDUFS1003;NDUFS1004;NDUFS1005;NDUFS1006;NDUFS1007;NDUFS1008;NDUFS1009;NDUFS1009;NDUFS1010;NDUFS1011;NDUFS1012;NDUFS1013;NDUFS1014;NDUFS1015;NDUFS1016;NDUFS1017;NDUFS1018;NDUFS1019;NDUFS1019;NDUFS1020;NDUFS1021;NDUFS1022;NDUFS1023;NDUFS1024;NDUFS1025;NDUFS1026;NDUFS1027;NDUFS1028;NDUFS1029;NDUFS1029;NDUFS1030;NDUFS1031;NDUFS1032;NDUFS1033;NDUFS1034;NDUFS1035;NDUFS1036;NDUFS1037;NDUFS1038;NDUFS1039;NDUFS1039;NDUFS1040;NDUFS1041;NDUFS1042;NDUFS1043;NDUFS1044;NDUFS1045;NDUFS1046;NDUFS1047;NDUFS1048;NDUFS1049;NDUFS1049;NDUFS1050;NDUFS1051;NDUFS1052;NDUFS1053;NDUFS1054;NDUFS1055;NDUFS1056;NDUFS1057;NDUFS1058;NDUFS1059;NDUFS1059;NDUFS1060;NDUFS1061;NDUFS1062;NDUFS1063;NDUFS1064;NDUFS1065;NDUFS1066;NDUFS1067;NDUFS1068;NDUFS1069;NDUFS1069;NDUFS1070;NDUFS1071;NDUFS1072;NDUFS1073;NDUFS1074;NDUFS1075;NDUFS1076;NDUFS1077;NDUFS1078;NDUFS1079;NDUFS1079;NDUFS1080;NDUFS1081;NDUFS1082;NDUFS1083;NDUFS1084;NDUFS1085;NDUFS1086;NDUFS1087;NDUFS1088;NDUFS1089;NDUFS1089;NDUFS1090;NDUFS1091;NDUFS1092;NDUFS1093;NDUFS1094;NDUFS1095;NDUFS1096;NDUFS1097;NDUFS1098;NDUFS1099;NDUFS1099;NDUFS1100;NDUFS1101;NDUFS1102;NDUFS1103;NDUFS1104;NDUFS1105;NDUFS1106;NDUFS1107;NDUFS1108;NDUFS1109;NDUFS1109;NDUFS1110;NDUFS1111;NDUFS1112;NDUFS1113;NDUFS1114;NDUFS1115;NDUFS1116;NDUFS1117;NDUFS1118;NDUFS1119;NDUFS1119;NDUFS1120;NDUFS1121;NDUFS1122;NDUFS1123;NDUFS1124;NDUFS1125;NDUFS1126;NDUFS1127;NDUFS1128;NDUFS1129;NDUFS1129;NDUFS1130;NDUFS1131;NDUFS1132;NDUFS1133;NDUFS1134;NDUFS1135;NDUFS1136;NDUFS1137;NDUFS1138;NDUFS1139;NDUFS1139;NDUFS1140;NDUFS1141;NDUFS1142;NDUFS1143;NDUFS1144;NDUFS1145;NDUFS1146;NDUFS1147;NDUFS1148;NDUFS1149;NDUFS1149;NDUFS1150;NDUFS1151;NDUFS1152;NDUFS1153;NDUFS1154;NDUFS1155;NDUFS1156;NDUFS1157;NDUFS1158;NDUFS1159;NDUFS1159;NDUFS1160;NDUFS1161;NDUFS1162;NDUFS1163;NDUFS1164;NDUFS1165;NDUFS1166;NDUFS1167;NDUFS1168;NDUFS1169;NDUFS1169;NDUFS1170;NDUFS1171;NDUFS1172;NDUFS1173;NDUFS1174;NDUFS1175;NDUFS1176;NDUFS1177;NDUFS1178;NDUFS1179;NDUFS1179;NDUFS1180;NDUFS1181;NDUFS1182;NDUFS1183;NDUFS1184;NDUFS1185;NDUFS1186;NDUFS1187;NDUFS1188;NDUFS1189;NDUFS1189;NDUFS1190;NDUFS1191;NDUFS1192;NDUFS1193;NDUFS1194;NDUFS1195;NDUFS1196;NDUFS1197;NDUFS1198;NDUFS1199;NDUFS1199;NDUFS1200;NDUFS1201;NDUFS1202;NDUFS1203;NDUFS1204;NDUFS1205;NDUFS1206;NDUFS1207;NDUFS1208;NDUFS1209;NDUFS1209;NDUFS1210;NDUFS1211;NDUFS1212;NDUFS1213;NDUFS1214;NDUFS1215;NDUFS1216;NDUFS1217;NDUFS1218;NDUFS1219;NDUFS1219;NDUFS1220;NDUFS1221;NDUFS1222;NDUFS1223;NDUFS1224;NDUFS1225;NDUFS1226;NDUFS1227;NDUFS1228;NDUFS1229;NDUFS1229;NDUFS1230;NDUFS1231;NDUFS1232;NDUFS1233;NDUFS1234;NDUFS1235;NDUFS1236;NDUFS1237;NDUFS1238;NDUFS1239;NDUFS1239;NDUFS1240;NDUFS1241;NDUFS1242;NDUFS1243;NDUFS1244;NDUFS1245;NDUFS1246;NDUFS1247;NDUFS1248;NDUFS1249;NDUFS1249;NDUFS1250;NDUFS1251;NDUFS1252;NDUFS1253;NDUFS1254;NDUFS1255;NDUFS1256;NDUFS1257;NDUFS1258;NDUFS1259;NDUFS1259;NDUFS1260;NDUFS1261;NDUFS1262;NDUFS1263;NDUFS1264;NDUFS1265;NDUFS1266;NDUFS1267;NDUFS1268;NDUFS1269;NDUFS1269;NDUFS1270;NDUFS1271;NDUFS1272;NDUFS1273;NDUFS1274;NDUFS1275;NDUFS1276;NDUFS1277;NDUFS1278;NDUFS1279;NDUFS1279;NDUFS1280;NDUFS1281;NDUFS1282;NDUFS1283;NDUFS1284;NDUFS1285;NDUFS1286;NDUFS1287;NDUFS1288;NDUFS1289;NDUFS1289;NDUFS1290;NDUFS1291;NDUFS1292;NDUFS1293;NDUFS1294;NDUFS1295;NDUFS1296;NDUFS1297;NDUFS1298;NDUFS1299;NDUFS1299;NDUFS1300;NDUFS1301;NDUFS1302;NDUFS1303;NDUFS1304;NDUFS1305;NDUFS1306;NDUFS1307;NDUFS1308;NDUFS1309;NDUFS1309;NDUFS1310;NDUFS1311;NDUFS1312;NDUFS1313;NDUFS1314;NDUFS1315;NDUFS1316;NDUFS1317;NDUFS1318;NDUFS1319;NDUFS1319;NDUFS1320;NDUFS1321;NDUFS1322;NDUFS1323;NDUFS1324;NDUFS1325;NDUFS1326;NDUFS1327;NDUFS1328;NDUFS1329;NDUFS1329;NDUFS1330;NDUFS1331;NDUFS1332;NDUFS1333;NDUFS1334;NDUFS1335;NDUFS1336;NDUFS1337;NDUFS1338;NDUFS1339;NDUFS1339;NDUFS1340;NDUFS1341;NDUFS1342;NDUFS1343;NDUFS1344;NDUFS1345;NDUFS1346;NDUFS1347;NDUFS1348;NDUFS1349;NDUFS1349;NDUFS1350;NDUFS1351;NDUFS1352;NDUFS1353	

eTable 3: Demographic, Clinical and Genetic Information for Subjects with Disease-relevant Variants or Variants of Uncertain Significance in the Nuclear Genome

ID	Age	Sex	Family History	Clinical features	Nijmegen rating	Muscle biopsy	Changes on muscle biopsy	Gene	Mode	Reference sequence	Genomic change (GRCh37)	Nucleotide and amino acid change	Zygosity	Variant previously reported [e ref]	ACMG
Disease Relevant Variants															
B45	47	F	Y	Stroke-like episodes, migraines, generalized tonic-clonic seizures	Probable	N	N/A	AMACR	AR	NM_014324.5; NP_055139.4	chr5:g.34007971A>G	c.154T>C; p.Ser52Pro	Hom	Y[e 1]	Pathogenic, PS1, PS3, PP3
E19	46	F	Y	Stroke-like episodes, migraines, seizures, encephalopathy, myoclonic jerks, retinitis pigmentosa, myopathy	Probable	N	N/A	AMACR	AR	NM_014324.5; NP_055139.4	chr5:g.34007971A>G	c.154T>C; p.Ser52Pro	Hom	Y[e 1]	Pathogenic, PS1, PS3, PP3
E28	47	F	N	Stroke-like episodes, migraines, seizures, muscle weakness, retinitis pigmentosa	Probable	Y	N	AMACR	AR	NM_014324.5; NP_055139.4	chr5:g.34007971A>G	c.154T>C; p.Ser52Pro	Het	Y[e 1]	Pathogenic, PS1, PS3, PP3
											chr5:g.34005988GAGT TTCTCC>G	c.255_263delGGAGAA ACT; p.Met85_Leu88delinsle	Het	N	Likely pathogenic, PS3, PM2, PM4
F3	61	M	N	Myopathy, fasciculations, lipomatosis, mild axonal neuropathy on nerve biopsy, dystrophic changes with rimmed vacuoles on muscle biopsy	Possible	Y	N	MFN2	AR	NM_014874.3, NP_055689.1	chr1:g.12069698C>T	c.2119C>T; p.Arg707Trp	Hom	Y[e 2]	Likely pathogenic, PS1, PP2, PP3
B44	48	M	N	Myopathy, axonal sensorimotor neuropathy, lipodystrophy around the neck, scoliosis	Possible	N	N/A	MFN2	AR	NM_014874.3, NP_055689.1	chr1:g.12057436C>CT	c.558dupT, p.Lys187Ter	Het	N	Pathogenic, PVS1, PM1, PM2, PP3
											chr1:g.12069698C>T	c.2119C>T; p.Arg707Trp	Het	Y[e 2]	Likely pathogenic, PS1, PP2, PP3
B42	57	F	Y	CPEO, proximal muscle weakness, bulbar involvement	Possible	N	N/A	MUSK†	AR	NC_000009.12 (NM_005592.3), NP_005583.1	chr9:g.113449551G>T	c.358+3G>T	Hom	N	Likely pathogenic, PS3, PM2, PP3
B43	72	M	Y	CPEO, proximal muscle weakness, bulbar involvement	Possible	Y	Y	MUSK†	AR	NC_000009.12 (NM_005592.3), NP_005583.1	chr9:g.113449551G>T	c.358+3G>T	Hom	N	Likely pathogenic, PS3, PM2, PP3
B21	61	F	N	CPEO, sensory neuropathy, migraines, neuropathy, COX negative and RRFs on muscle biopsy	Definite	Y	Y	POLG	AR	NM_002693.2, NP_002684.1	chr15:g.89868870G>A: in cis g.89873415G>A	c.1760C>T; p.Pro587Leu: in cis c.752C>T; p.Thr251Ile	Hom	Y[e 3, 4]	Likely pathogenic, PS1, PP3, PP5
E8	65	M	N	CPEO, proximal muscle weakness, dysphagia, neuropathy, diabetes, hearing loss	Probable	N	N/A	POLG	AR	NM_002693.2, NP_002684.1	chr15:g.89868870G>A: in cis g.89873415G>A	c.1760C>T; p.Pro587Leu: in cis c.752C>T; p.Thr251Ile	Hom	Y[e 3, 4]	Likely pathogenic, PS1, PP3, PP5

E81	70	M	N	CPEO, myopathy, diabetes, neuropathy, elevated lactate on MRS, COX negative and RRFs on muscle biopsy	Definite	Y	Y	POLG	AR	NM_002693.2, NP_002684.1	chr15:g.89868870G>A: in cis g.89873415G>A	c.1760C>T; p.Pro587Leu: in cis c.752C>T; p.Thr251Ile	Hom	Y[e 3, 4]	Likely pathogenic, PS1, PP3, PP5
B28	60	F	N	CPEO, proximal myopathy, diabetes, COX negative and RRFs on muscle biopsy	Definite	Y	Y	POLG	AR	NM_002693.2, NP_002684.1	chr15:g.89870432C>T	c.1399G>A; p.Ala467Thr	Het	Y[e 5]	Likely pathogenic, PS1, PM3, PP3
											chr15:g.89872174C>T	c.1023G>A (splice region)	Het	N	Likely pathogenic, PS3, PM2, PP3
B46	69	F	N	CPEO, hearing impairment, proximal myopathy, COX negative fibers on muscle biopsy	Probable	Y	Y	POLG	AR	NM_002693.2, NP_002684.1	chr15:g.89868870G>A: in cis g.89873415G>A	c.1760C>T; p.Pro587Leu: in cis c.752C>T; p.Thr251Ile	Het	Y[e 3, 4]	Likely pathogenic, PS1, PP3, PP5
											chr15:g.89866669A>AT GTCCACGTCGTG	c.2217_2230dupCAAC GACGTGGACA; p.Ile744ThrsTer59	Het	N	Pathogenic, PVS1, PM2, PP5
B51	49	F	N	CPEO, proximal and distal weakness, GI dysmotility, sensorimotor polyneuropathy, COX negative, SDH positive, RRFs on muscle biopsy	Definite	Y	Y	POLG	AR	NM_002693.2, NP_002684.1	chr15:g.89865014T>C	c.2551A>G; p.Thr851Ala	Het	Y[e 6] and published previously [e 7]	Likely pathogenic, PS1, PM2, PP3
											chr15:g.89870429T>C	c.1402A>G; p.Asn468Asp	Het	Y[e 8] and previously published [e 7]	Likely pathogenic, PS1, PM3, BP4
B59	40	F	N	SANDO	Probable	N	N/A	POLG	AR	NM_002693.2, NP_002684.1	chr15:g.89870432C>T	c.1399G>A; p.Ala467Thr	Hom	Y[e 9]	Likely pathogenic, PS1, PM3, PP3
C17	54	M	Y	CPEO, dysphagia, hearing impairment, proximal myopathy, exercise intolerance, left anterior hemiblock, COX negative and RRFs on muscle biopsy	Probable	Y	Y	POLG	AR	NM_002693.2, NP_002684.1	chr15:g.89864238T>G	c.2740A>C; p.Thr914Pro	Het	Y[e 10]	Likely pathogenic, PS1, PM3, PP3
											chr15:g.89866637T>G	c.2263A>C; p.Lys755Gln	Het	Reported missense at the same position [e 11]	VUS – favor pathogenic, PM2, PM3, PP3
C27	54	F	N	CPEO, mild sensory axonal neuropathy, encephalopathy, paranoia, hallucinations, GI dysmotility, cognitive impairment, mitochondrial myopathy with COX negative and RRFs on muscle biopsy	Definite	Y	Y	POLG	AR	NM_002693.2, NP_002684.1	chr15:g.89869871G>A	c.1684C>T; p.Arg562Trp	Het	N	Likely pathogenic, PM2, PM3, PM5, PP3
											chr15:g.89870432C>T	c.1399G>A; p.Ala467Thr	Het	Y[e 9]	Likely pathogenic, PS1, PM3, PP3
F5	26	F	N	SANDO, seizures, tremor, visual hallucinations, GI dysmotility	Probable	N	N/A	POLG	AR	NM_002693.2, NP_002684.1	chr15:g.89866657C>G	c.2243G>C; p.Trp748Ser	Het	Y[e 12]	Likely pathogenic, PS1, PP3, PP5
											chr15:g.89870432C>T	c.1399G>A; p.Ala467Thr	Het	Y[e 9]	Likely pathogenic, PS1, PM3, PP3

E73	59	F	N	CPEO, hearing loss, myopathy	Probable	N	N/A	POLG	AR	NM_002693.2, NP_002684.1	chr15:g.89865001A>G	c.2564T>C; p.Val855Ala	Hom	Y[e 13]	Likely pathogenic, PS1, PM2, PP3
C9	53	F	Y	CPEO, spastic paraparesis, dysarthria, ataxia, Oxidative enzymes normal on muscle biopsy	Possible	Y	N	SPG7	AR	NC_000016.9(NM_003119.2), NP_003110.1	chr16:g.89623293A>G	c.2182-2A>G	Hom	N	Pathogenic, PVS1, PM2, PP3
E41	60	F	Y	CPEO, spastic paraparesis, cerebellar ataxia, blepharospasm, cervical dystonia	Probable	Y	N	SPG7	AR	C_000016.9(NM_003119.2), NP_003110.1	chr16:g.89623293A>G	c.2182-2A>G	Hom	N	Pathogenic, PVS1, PM2, PP3
E75	64	M	Y	CPEO, ataxia, spastic paraparesis, neuropathy, muscle biopsy consistent with a denervation process	Definite	Y	N	SPG7	AR	NM_003119.2, NP_003110.1	chr16:g.89595397-89596343del	946 bp deletion	Hom	N	Likely pathogenic, PVS1, PM2
B57	43	M	Y	CPEO, neuropathy, gastric dysmotility, weight loss, myopathy	Possible	N	N/A	TYMP	AR	NM_00111375 5.1, NP_00110722 7.1	chr22:g.50964300GCC GCTGAGCGCGGGG CCGTC>G	c.1228_1247delGACG GCCCGCGCTCAGC GG; p.Asp410ProfsTer?	Hom	Y[e 14]	Likely pathogenic, PVS1, PM2
E45	24	F	N	CPEO, neuropathy, gastric dysmotility, weight loss, myopathy, SDH positive and RRFs on muscle biopsy	Probable	Y	Y	TYMP	AR	NM_00111375 5.1, NP_00110722 7.1	chr22:g.50964903C>A	c.931G>T; p.Gly311Cys	Het	Y[e 15] and reported previously [e 14]	Pathogenic, PS1, PS3, PP3
											chr22:g.50964336GC>G	c.1311delG; p.Trp437Cysfs?	Het	Y[e 29] and previously reported [e 14]	Pathogenic, PVS1, PS1, PP3
E86	30	M	Y	CPEO, neuropathy, myopathy, ataxia, COX negative, SDH positive and RRFs on muscle biopsy	Definite	Y	Y	TYMP	AR	NM_00111375 5.1, NP_00110722 7.1	chr22:g.50964300GCC GCTGAGCGCGGGG CCGTC>G	c.1228_1247delGACG GCCCGCGCTCAGC GG; p.Asp410ProfsTer?	Hom	Y[e 14]	Likely pathogenic, PVS1, PM2
E55	31	F	N	Wolfram syndrome; diabetes mellitus, diabetes insipidus, optic atrophy, hearing loss	Probable	N	N/A	WFS1‡	AR	NM_006005.3, NP_005996.2	chr4:g.6302761TTCG>T	c.1243_1245delGTC; p.Val415del	Het	Y[e 16]	Likely pathogenic, PS1, PM2, PM4
											chr4:g.6303622G>T	c.2100G>T, p.Trp700Cys	Het	Y[e 16]	Likely pathogenic, PS1, PM2, PP3, PP5
B60	25	F	N	Myopathy, exercise intolerance, sideroblastic anemia, lactic acidosis, GI dysmotility, (MLASA), COX negative fibers on muscle biopsy	Definite	Y	Y	YARS2	AR	NM_00104043 6.2, NP_00103552 6.1	chr12:g.32908653G>C	c.156C>G; p.Phe52Leu	Hom	Y[e 17]	Likely pathogenic, PS1, PM2, PP3, PP5
C44	33	F	N	Ptosis, optic atrophy, proximal myopathy, fatigue, respiratory muscle weakness, cardiomyopathy, mitochondrial myopathy on muscle biopsy (respiratory chain enzyme analysis showed significant deficit in complex I and IV and moderate deficit in complex III, sparing of complex II)	Definite	Y	Y	YARS2	AR	NM_00104043 6.2, NP_00103552 6.1	chr12:g.32908711G>T	c.98C>A; p.Ser33Ter	Het	N	Pathogenic, PVS1, PM2, PP3
											chr12:g.32903808C>A	c.948G>T; p.Arg316Ser	Het	N	VUS-favor pathogenic, PM2, PM3
B20	41	F	N	CPEO, gestational diabetes, spasticity, mitochondrial myopathy, COX positive and RRFs on muscle biopsy	Definite	Y	Y	AFG3L2	AD	NC_000018.10 (NM_006796.2) ;NP_006787.2	chr18:g.12370846A>G	c.292+2T>C	Het	Likely pathogenic on ClinVar	Pathogenic, PVS1, PM2, PP3

B7	64	F	Y	CPEO, neuropathy, insulin resistance, myalgias, fatigue, COX negative and RRFs on muscle biopsy	Definite	Y	Y	TWNK	AD	NM_021830.4; NP_068602.2	chr10:g.102748874C>T	c.907C>T; p.Arg303Trp	Het	Y[e 18]	Pathogenic, PS1, PM2, PM5, PP2, PP3
B29	58	F	Y	CPEO, RRFs on muscle biopsy	Probable	Y	Y	TWNK	AD	NM_021830.4; NP_068602.2	chr10:g.102749589T>G	c.1432T>G; p.Phe478Val	Het	Missense at the same position reported [e 19]	Likely pathogenic, PM1, PM2, PM5, PP2, PP3
C1	51	M	Y	CPEO, muscle fatigue, gastric dysmotility, proteinuria, neuropathy, COX negative and RRFs on muscle biopsy	Definite	Y	Y	TWNK	AD	NM_021830.4; NP_068602.2	chr10:g.102749610T>A	c.1453T>A; p.Phe485Ile	Het	N	Likely pathogenic, PM1, PM2, PP2, PP3
C10	68	F	Y	CPEO, proximal myopathy, COX negative and RRFs on muscle biopsy	Probable	Y	Y	TWNK	AD	NM_021830.4; NP_068602.2	chr10:g.102749610T>A	c.1453T>A; p.Phe485Ile	Het	N	Likely pathogenic, PM1, PM2, PP2, PP3
C29	69	F	N	CPEO, proximal myopathy, dysphagia, fatigue, mitochondrial myopathy, COX negative and RRFs on muscle biopsy	Probable	Y	Y	TWNK	AD	NM_021830.4; NP_068602.2	chr10:g.102749037G>C	c.1070G>C; p.Arg357Pro	Het	Y[e 20]	Likely pathogenic, PS1, PM2, PP2, PP3
C33	48	F	N	CPEO, proximal myopathy, muscle fatigue	Possible	N	N/A	TWNK	AD	NM_021830.4; NP_068602.2	chr10:g.102749535G>C	c.1378G>C; p.Ala460Pro	Het	Y[e 21]	Pathogenic, PS1, PM1, PM2, PP2, PP3
C40	39	F	Y	CPEO, migraine, hearing loss, gastric dysmotility, gestational diabetes	Probable	N	N/A	TWNK	AD	NM_021830.4; NP_068602.2	chr10:g.102749073C>A	c.1106C>A; p.Ser369Tyr	Het	Y[e 22]	Pathogenic, PS1, PM1, PM2, PM5, PP2, PP3
C41	62	F	Y	CPEO, proximal myopathy, GI dysmotility, hearing loss, migraines	Probable	N	N/A	TWNK	AD	NM_021830.4; NP_068602.2	chr10:g.102749073C>A	c.1106C>A; p.Ser369Tyr	Het	Y[e 22]	Pathogenic, PS1, PM1, PM2, PM5, PP2, PP3
D3	64	F	Y	CPEO, hearing impairment, insulin resistance, mitochondrial myopathy COX negative and RRFs on muscle biopsy	Definite	Y	Y	TWNK	AD	NM_021830.4; NP_068602.2	chr10:g.102748923A>G	c.956A>G; p.Lys319Arg	Het	Missense at the same position reported [e 23]	Likely pathogenic, PM2, PM5, PP2, PP3
D8	46	F	Y	CPEO, exercise intolerance, Grave's disease	Possible	N	N/A	TWNK	AD	NM_021830.4; NP_068602.2	chr10:g.102748923A>G	c.956A>G; p.Lys319Arg	Het	Missense at the same position reported [e 23]	Likely pathogenic, PM2, PM5, PP2, PP3
C24	23	F	Y	CPEO, dominant optic atrophy plus, hearing impairment, mild ataxia	Probable	N	N/A	OPA1	AD	NM_015560.2, NP_056375.2	chr3:g.193361785G>A	c.1334G>A; p.Arg445His	Het	Y[e 23]	Pathogenic, PS1, PM1, PM2, PM5, PP2, PP3
C46	54	F	Y	CPEO, myopathy, dominant optic atrophy plus, hearing impairment, neuropathy, cognitive impairment	Probable	N	N/A	OPA1	AD	NM_015560.2, NP_056375.2	chr3:g.193361785G>A	c.1334G>A; p.Arg445His	Het	Y[e 24]	Pathogenic, PS1, PM1, PM2, PM5, PP2, PP3

E1	74	F	Y	Dominant optic atrophy, ovarian failure, hearing loss	Possible	N	N/A	OPA1	AD	NM_015560.2, NP_056375.2	chr3:g.193361764A>G	c.1313A>G; p.Asp438Gly	Het	Y[e 25]	Pathogenic, PS1, PM1, PM2, PM5, PP2, PP3
E25	44	F	Y	Dominant optic atrophy, ovarian failure	Possible	N	N/A	OPA1	AD	NM_015560.2, NP_056375.2	chr3:g.193361764A>G	c.1313A>G; p.Asp438Gly	Het	Y[e 26]	Pathogenic, PS1, PM1, PM2, PM5, PP2, PP3
E10	14	M	Y	Dominant optic atrophy, mild spasticity with clonus	Possible	N	N/A	OPA1	AD	NM_015560.2, NP_056375.2	chr3:g.193349431C>T	c.655C>T; p.Gln219Ter	Het	Y[e 26]	Pathogenic, PVS1, PS1, PM2, PP3
E11	53	F	Y	Dominant optic atrophy	Possible	N	N/A	OPA1	AD	NM_015560.2, NP_056375.2	chr3:g.193349431C>T	c.655C>T; p.Gln219Ter	Het	Y[e 26]	Pathogenic, PVS1, PS1, PM2, PP3
E14	40	M	Y	Dominant optic atrophy, diabetes	Possible	N	N/A	OPA1	AD	NM_015560.2, NP_056375.2	chr3:g.193361776A>G	c.1325A>G; p.Asp442Gly	Het	Likely pathogenic on ClinVar	Likely pathogenic, PM1, PM2, PM5, PP2, PP3
E22	61	F	Y	Dominant optic atrophy, muscle weakness and neuropathy	Possible	N	N/A	OPA1	AD	NM_015560.2, NP_056375.2	chr3:g.193361776A>G	c.1325A>G; p.Asp442Gly	Het	Likely pathogenic on ClinVar	Likely pathogenic, PM1, PM2, PM5, PP2, PP3
E87	67	M	Y	CPEO, dominant optic atrophy, ataxia, neuropathy	Probable	N	N/A	OPA1	AD	NM_015560.2, NP_056375.2	chr3:g.193355758T>A	c.888T>A; p.Asp296Glu	Het	Previously published [e 27]	Likely pathogenic, PM1, PM2, PP1, PP2, PP3
E88	72	F	Y	CPEO, dominant optic atrophy plus, hearing loss, sensory neuropathy, ataxia, migraine	Definite	N	N/A	OPA1	AD	NM_015560.2, NP_056375.2	chr3:g.193355758T>A	c.888T>A; p.Asp296Glu	Het	Previously published [e 27]	Likely pathogenic, PM1, PM2, PP1, PP2, PP3
E89	70	F	Y	CPEO, dominant optic atrophy plus, proximal myopathy, ataxia	Probable	N	N/A	OPA1	AD	NM_015560.2, NP_056375.2	chr3:g.193355758T>A	c.888T>A; p.Asp296Glu	Het	Previously published [e 27]	Likely pathogenic, PM1, PM2, PP1, PP2, PP3
E90	41	F	Y	Dominant optic atrophy, neuropathy	Possible	N	N/A	OPA1	AD	NM_015560.2, NP_056375.2	chr3:g.193355758T>A	c.888T>A; p.Asp296Glu	Het	Previously published [e 27]	Likely pathogenic, PM1, PM2, PP1, PP2, PP3
E91	42	F	Y	Dominant optic atrophy	Possible	N	N/A	OPA1	AD	NM_015560.2, NP_056375.2	chr3:g.193355758T>A	c.888T>A; p.Asp296Glu	Het	Previously published [e 27]	Likely pathogenic, PM1, PM2, PP1, PP2, PP3
E94	41	F	Y	CPEO, dominant optic atrophy plus, mild cerebellar ataxia, neuropathy	Possible	N	N/A	OPA1	AD	NM_015560.2, NP_056375.2	chr3:g.193355758T>A	c.888T>A; p.Asp296Glu	Het	Previously published [e 27]	Likely pathogenic, PM1, PM2, PP1, PP2, PP3
E95	39	M	Y	CPEO, dominant optic atrophy plus, hearing impairment, proximal myopathy	Probable	N	N/A	OPA1	AD	NM_015560.2, NP_056375.2	chr3:g.193355758T>A	c.888T>A; p.Asp296Glu	Het	Previously published [e 27]	Likely pathogenic, PM1, PM2, PP1, PP2, PP3

E97	69	F	Y	CPEO, dominant optic atrophy plus, diabetes, hearing loss, ataxia, proximal myopathy	Probable	N	N/A	OPA1	AD	NM_015560.2, NP_056375.2	chr3:g.193355758T>A	c.888T>A; p.Asp296Glu	Het	Previously published [e 27]	Likely pathogenic, PM1, PM2, PP1, PP2, PP3
C36	47	F	Y	CPEO, dysphagia, proximal myopathy, peripheral neuropathy	Possible	N	N/A	POLG	AD	NM_002693.2, NP_002684.1	chr15:g.89864114T>C	c.2864A>G; p.Tyr955Cys	Het	Y [e 28]	Likely pathogenic, PS1, PM2, PP3
B39	58	M	N	McLeod neuroacanthocytosis syndrome; bilateral ptosis, proximal myopathy, seizures, multiple frequent tics, acanthocytes, COX negative and RRFs on muscle biopsy	Probable	Y	Y	XK‡	XLR	NM_021083.2, NP_066569.1	chrX:g.37553559CT>C	c.268delT; p.Tyr90ThrfsTer40	Het	N	Pathogenic, PVS1, PM2, PP3
B3	38	F	N	Mild CPEO, proximal weakness, seizures, colonic pseudo-obstructions, diabetes, cerebellar ataxia, elevated lactate	Probable	N	N/A	Numerous‡	De novo	GRCh37/hg19	chr4:g.119266501_1356 89400del		Het	N	Pathogenic PVS1, PM2
Variant of Uncertain Significance (VUS)															
D11	43	F	N	Stroke-like episodes, seizures, ptosis, COX negative fibers on muscle biopsy	Definite	Y	Y	ACAD9	AR	NC_000003.12 (NM_014049.4), NP_054768.2	chr3:g.128628253C>T	c.1552C>T p.Arg518Cys	Het	Y [e 29]	Likely pathogenic, PS1, PM2, PP3, PP5
											chr3:g.128614267A>G	c.453+8A>G	Het	N	VUS, BP4
E12	44	F	Y	CPEO, myopathy, dysphagia, neuropathy, multiple intracranial meningiomas	Possible	N	N/A	POLG	AR	NM_002693.2, NP_056375.2	chr15:g.89864968C>G	c.2597G>C p.Arg866Pro	Het	VUS on ClinVar	VUS, PM2, PP3
											chr15:g.89872242T>C	c.955A>G p.Lys319Glu	Het	N	VUS, PM2, PP3
B11	44	M	Y	Myalgias, myopathy, COX negative and RRFs on muscle biopsy	Possible	Y	Y	ALDH1B1‡	AD	NM_002860.3, NM_002860.3	chr10:g.97387286T>G	c.991A>C p.Thr331Pro	Het	Uncertain significance on ClinVar	VUS, PM2
B2	46	F	N	Stroke-like episodes, myopathy, migraines, cyclic neutropenia, complex I deficiency on muscle biopsy	Probable	Y	Y	TWNK	AD	NM_021830.4, NP_068602.2	chr10:g.102748082C>T	c.115C>T p.Arg39Cys	Het	N	VUS, PM2, PP2
B25	63	F	N	CPEO, proximal myopathy, ataxia, diabetes mellitus, gastrointestinal dysmotility, neuropathy, scattered fibers with oxidative enzyme abnormalities	Probable	Y	N	TWNK	AD	NM_021830.4, NP_068602.2	chr10:g.102748208C>G	c.241C>G p.Leu81Val	Het	Uncertain significance on ClinVar	VUS, PP2
E37	41	F	N	CPEO, myopathy, ataxia, spastic paraparesis	Possible	N	N/A	KIF5A‡	AD	NM_004984.2, NP_004975.2	chr12:g.57965888G>T	c.1407G>T p.Glu469Asp	Het	N	VUS, PP2
C43	68	M	N	Ptosis, muscle weakness and fatigue, seizures	Possible	N	N/A	OPA1	AD	NM_015560.2, NP_056375.2	chr3:g.193332585TTTC ACGAAGCATTTATCA>T	c.113_130delGAAGCA TTTATCATTAC; p.Arg38_Ser43del	Het	Y [e 30] Uncertain significance on ClinVar	VUS, PM4

B33	65	M	N	Stroke-like episodes, encephalopathy, migraine, hearing loss, gastric dysmotility, COX negative and RRFs on muscle biopsy	Definite	Y	Y	POLG	AD	NM_002693.2, NP_056375.2	chr15:g.89861908T>C	c.3346A>G p.Met1116Val	Het	VUS on ClinVar	VUS, PM2, PM5, PP3
C34	68	F	Y	Ptosis, muscle weakness, migraines, hearing loss, neuropathy, COX negative and RRFs on muscle biopsy	Definite	Y	Y	POLG	AD	NM_002693.2, NP_056375.2	chr15:g.89861859C>T	c.3395G>A p.Ser1132Asn	Het	N	VUS, PM2, PP3
C39	76	F	N	Proximal myopathy, hearing impairment, insulin resistance, raised lactate, COX negative, COX positive and RRFs on muscle biopsy	Definite	Y	Y	POLG	AD	NM_002693.2, NP_056375.2	chr15:g.89862265A>T	c.3170T>A p.Met1057Lys	Het	N	VUS, PM2, PP3
C11	41	M	N	Myalgias, fatigue, spastic paraparesis, hearing impairment, short stature, seizures, COX negative and RRFs on muscle biopsy	Definite	Y	Y	POLG2	AD	NM_007215.3, NP_009146.2	chr17:g.62481897G>A	c.1058C>T p.Ser353Phe	Het	N	VUS, PP3

ID = Patient identification number for this study; F = Female; M = Male; Y = Yes; N = No; N/A = Not Applicable; COX = Cytochrome Oxidase; CPEO = Chronic Progressive External Ophthalmoplegia; GI = Gastrointestinal; MRS = Magnetic Resonance Spectroscopy; RRF = Ragged Red Fibers; SANDO = Sensory Ataxia, Neuropathy, Dysarthria and Ophthalmoplegia; SDH = Succinate Dehydrogenase; Nijmegen Rating = Classifications according to the Nijmegen criteria – Definite = score of 8-12, Probable = score of 5-7, Possible = score of 2-4; ‡ = Mitochondrial mimic; Mode = Mode of inheritance; AD = Autosomal Dominant; AR = Autosomal Recessive; Het = Heterozygous; Hom = Homozygous; VUS = Variant of Uncertain Significance; ACMG Classification = Classification according to the American College of Medical Genetics criteria.

eTable 4: Mitochondrial DNA variants identified using Whole Genome Sequencing

ID	Age	Sex	Family History	Clinical features	Nijmegen rating	Muscle biopsy	Changes on muscle biopsy	Gene	Mode	Nucleotide and amino acid change (GRCh37)	WGS plasmY (Pyroseq plasmY)
B32	64	M	Y	Hearing impairment, myalgia, generalized large fiber neuropathy, COX negative, SDH positive and RRFs on muscle biopsy (atypical presentation)	Probable	Y	Y	<i>MT-RNR1</i>	Mat	m.1555A>G	85%
E27	41	F	Y	Migraines	Possible	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	19% (19%)
E29	80	F	Y	Proximal myopathy, retinal pigmentary changes	Possible	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	1% (1%)
E30	29	M	Y	Migraines, diabetes, hearing loss, Wolf-Parkinson's-White syndrome	Definite	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	32% (32%)
E33	37	F	Y	Muscle weakness, migraines, GI dysmotility, mitral valve prolapse	Probable	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	23% (23%)
F11	57	M	Y	Myopathy, hearing loss, GI dysmotility, hypothyroidism	Probable	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	11% (9%)
E34	40	M	Y	Proximal myopathy, CPEO, dysphagia, lactic acidosis, hearing loss, diabetes, cardiac conduction block	Probable	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	28% (27%)
B49	56	M	Y	Diabetes, hearing loss	Probable	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	12% (12%)
E35	49	M	Y	MELAS syndrome	Definite	Y	Y	<i>MT-TL1</i>	Mat	m.3243A>G	20% (22%)
E36	78	F	Y	hearing loss, retinal pigmentary changes, exercise intolerance	Possible	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	4% (4%)
B50	66	M	Y	MIDD, CPEO, cardiomyopathy	Probable	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	12% (12%)
F1	48	F	Y	Muscle fatigue	Possible	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	6% (6%)
E39	31	F	Y	Hearing loss, migraines, GI dysmotility	Probable	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	28% (26%)
D9	50	M	Y	Muscle pain, hearing loss, insulin resistance, elevated lactate on MRS	Possible	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	8% (10%)
E43	47	F	Y	MELAS syndrome, hearing loss, diabetes	Probable	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	17% (16%)
B52	61	F	Y	Migraines, mild encephalopathy, myoclonus, hearing loss, GI dysmotility, insulin resistance	Possible	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	2% (2%)
E100	16	M	Y	MELAS syndrome	Probable	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	53% (50%)
E101	12	F	Y	Migraines, short stature	Possible	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	54% (53%)

D10	51	M	Y	Exercise intolerance, hearing loss, diabetes mellitus, atrial fibrillation, left ventricular function abnormalities	Possible	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	6% (6%)
E46	48	M	Y	Proximal myopathy, hearing loss, diabetes mellitus, peripheral neuropathy, GI dysmotility, cardiac arrhythmia, lactic acidosis	Probable	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	13% (14%)
D5	20	M	N	MELAS syndrome	Probable	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	24% (25%)
B56	38	F	Y	Migraines, hearing loss, diabetes, elevated lactate on MRS	Probable	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	21% (22%)
E52	44	F	Y	Migraines, insulin resistance, exercise intolerance	Probable	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	3% (3%)
E53	57	F	Y	Mild proximal weakness	Possible	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	0.35% (1%)
E56	56	F	Y	Ptosis, proximal weakness, fatigue, myalgias, hearing loss, myopathy, RRFs on muscle biopsy	Definite	Y	Y	<i>MT-TL1</i>	Mat	m.3243A>G	2% (2%)
E57	24	M	Y	Myalgias, migraines	Possible	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	11% (11%)
E58	22	F	Y	Ptosis, hearing impairment, fatigue, GI dysmotility, mild peripheral neuropathy	Possible	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	42% (39%)
E59	53	F	Y	MELAS syndrome, hearing loss, gastric dysmotility, COX negative, SDH positive fibers on muscle biopsy	Definite	Y	Y	<i>MT-TL1</i>	Mat	m.3243A>G	16% (16%)
E60	50	F	Y	Mild proximal weakness, diabetes	Possible	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	13% (12%)
E65	74	F	Y	MELAS syndrome, hearing loss, GI dysmotility	Probable	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	48% (46%)
E9	45	M	Y	MELAS syndrome, myoclonus, hearing loss, COX negative and RRFs on muscle biopsy	Definite	Y	Y	<i>MT-TL1</i>	Mat	m.3243A>G	34% (32%)
E66	37	M	Y	Mild ptosis	Possible	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	26% (17%)
D2	45	F	Y	Muscle fatigue, hearing loss, GI dysmotility	Probable	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	18% (18%)
F10	42	F	Y	Muscle fatigue, hearing loss, GI dysmotility	Possible	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	18% (20%)
E68	42	F	Y	Muscle fatigue, hearing loss, insulin resistance	Possible	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	14% (16%)
E72	26	F	Y	Hearing loss, focal and segmental glomerulonephritis	Possible	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	37% (35%)
C45	53	F	Y	Myopathy, stroke-like episodes, migraines, hearing impairment, GI dysmotility, diabetes, renal impairment, lactic acidosis	Definite	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	20% (18%)
A7	45	M	Y	MELAS syndrome, diabetes, GI dysmotility, elevated lactate on MRS	Possible	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	24% (14%)

F8	78	F	Y	Stroke-like episodes, diabetes, hearing loss, GI dysmotility, Parkinsonism	Definite	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	0.45% (1%)
F9	40	M	Y	Hearing loss, GI dysmotility, migraines	Probable	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	18% (18%)
D17	27	M	Y	Myalgias, impaired glucose tolerance	Definite	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	34% (33%)
E20	61	F	Y	Myopathy, exercise intolerance, elevated lactate	Probable	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	2% (2%)
E79	19	M	Y	Short stature, exercise intolerance	Probable	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	21% (21%)
E80	47	F	Y	Diabetes, myopathy, exercise intolerance, hearing loss, GI dysmotility, neuropathy	Probable	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	17% (17%)
D20	60	F	Y	Myopathy, migraines, hearing loss, GI dysmotility, insulin resistance	Probable	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	9% (10%)
D4	35	F	Y	Migraines, seizures, myoclonic jerks, hearing loss, GI dysmotility	Probable	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	31% (25%)
E85	55	F	N	MELAS syndrome, hearing loss, GI dysmotility, COX positive and RRFs on muscle biopsy	Definite	Y	Y	<i>MT-TL1</i>	Mat	m.3243A>G	4% (3%)
C23	51	M	Y	MELAS syndrome, hearing loss, cardiomyopathy	Definite	N	N/A	<i>MT-TL1</i>	Mat	m.3243A>G	19% (20%)
E105	21	F	N	Myopathy, migraines, optic atrophy, hearing loss, GI dysmotility, diabetes mellitus	Probable	Y	Y	<i>MT-TL1</i>	Mat	m.3243A>G	3% (4%)
F2	70	F	Y	Hearing impairment, proximal myopathy, mild dysphagia, respiratory muscle weakness, mitochondrial myopathy on muscle biopsy	Probable	Y	Y	<i>MT-TL1</i>	Mat	m.3251A>G	7%
A4	29	M	Y	Oligosymptomatic, migraines	Possible	N	N/A	<i>MT-TL1</i>	Mat	m.3256C>T	24%
E82	31	M	Y	Myopathy, migraines, COX positive and RRFs on muscle biopsy	Definite	Y	Y	<i>MT-TL1</i>	Mat	m.3256C>T	4%
E83	25	F	Y	Exercise intolerance	Possible	N	N/A	<i>MT-TL1</i>	Mat	m.3256C>T	2%
E78	57	F	Y	Ptosis, proximal myopathy, ataxia, tremor, myoclonus, peripheral neuropathy, hearing loss, RRFs on muscle biopsy	Probable	Y	Y	<i>MT-TL1</i>	Mat	m.3302A>G	19%
E5	20	M	Y	LHON	Possible	N	N/A	<i>MT-ND1</i>	Mat	m.3460G>A; p.Ala52Thr	100%
E6	23	F	Y	Migraines	Possible	N	N/A	<i>MT-ND1</i>	Mat	m.3460G>A; p.Ala52Thr	100%
A6	52	M	Y	CPEO, myopathy, GI dysmotility, sensorimotor axonal neuropathy	Probable	N	N/A	<i>MT-T1</i>	Mat	m.4269A>G	26%
A1	66	F	Y	Proximal muscle weakness, migraines, myoclonus, early onset hearing loss, neuropathy, elevated lactate on MRS	Definite	N	N/A	<i>MT-TK</i>	Mat	m.8344A>G	70%

E23	20	F	Y	MERRF syndrome	Possible	N	N/A	MT-TK	Mat	m.8344A>G	92%
E103	69	F	Y	MERRF syndrome, renal impairment, lipomas, hearing loss, RRFs on muscle biopsy	Definite	Y	Y	MT-TK	Mat	m.8344A>G	95%
E51	37	M	Y	NARP	Probable	N	N/A	MT-ATP6	Mat	m.893T>G; p.Leu156Arg	90%
C7	28	M	N	Migraines, seizures, stroke-like episodes, hearing loss, lactic acidosis, complex I deficiency on muscle biopsy, abnormal mitochondria on EM	Probable	Y	Y	MT-ND3	Mat	m.10191T>C; p.Ser45Pro	32%
E3	57	F	Y	Oligosymptomatic, cervical dystonia, head tremor	Possible	N	N/A	MT-ND4	Mat	m.11778G>A; p.Arg340His	75%
E4	22	M	Y	LHON, postural tremor, myoclonus	Possible	N	N/A	MT-ND4	Mat	m.11778G>A; p.Arg340His	100%
A2	17	M	N	CPEO, optic atrophy, spasticity, hearing loss (atypical presentation)	Probable	N	N/A	MT-ND4	Mat	m.11778G>A; p.Arg340His	100%
A8	39	F	Y	LHON-MS (Harding's disease)	Possible	N	N/A	MT-ND4	Mat	m.11778G>A; p.Arg340His	100%
D18	27	M	N	MELAS syndrome, migraines, diabetes, hearing loss, Wolff-Parkinson-White syndrome, Complex I and IV deficiency on muscle biopsy	Probable	Y	Y	MT-ND5	Mat	m.13042G>A; p.Ala236Thr	6%
E2	45	F	Y	Bilateral optic neuropathy, hearing impairment, diabetes mellitus	Possible	N	N/A	MT-ND5	Mat	m.13513G>A; p.Asp393Asn	13%
E99	28	M	N	Leigh-like disease, mitochondrial disease on muscle biopsy ("parking lot" intracristal inclusions on electron microscopy)	Probable	Y	Y	MT-ND5	Mat	m.13528A>G; p.Thr398Ala	100%
A5	40	F	N	Proximal myopathy, RRFs on muscle biopsy	Probable	Y	Y	MT-TE	Mat	m.14674T>C	100%
E77	43	F	Y	Myalgia, fatigue, GI dysmotility, exercise intolerance, impaired glucose tolerance	Probable	N	N/A	MT-TE	Mat	m.14709T>C	65%
A10	18	F	N	KSS	Possible	N	N/A	Single deletion	Spo	Single deletion	0.29%
C16	16	F	N	KSS, COX negative and RRFs on muscle biopsy	Probable	Y	Y	Single deletion	Spo	Single deletion	0.60%

ID = Patient identification number for this study; F = Female; M = Male; Y = Yes; N = No; COX = Cytochrome Oxidase; CPEO = Chronic Progressive External Ophthalmoplegia; EM = Electron Microscopy; GI = Gastrointestinal; KSS = Kearns-Sayre Syndrome; LHON = Leber's Hereditary Optic Neuropathy; LHON-MS = Leber's Hereditary Optic Neuropathy with concurrent Multiple Sclerosis-like disease; MELAS = Mitochondrial Encephalopathy Lactic Acidosis and Stroke-like episodes; MERRF = Myoclonic Epilepsy with Ragged Red Fibers; MIDD = Maternally Inherited Diabetes and Deafness; MRS = Magnetic Resonance Spectroscopy; NARP = Neuropathy, Ataxia and Retinitis Pigmentosa; RRF = Ragged Red Fibers; SANDO = Sensory Ataxia, Neuropathy, Dysarthria and Ophthalmoplegia; SDH = Succinate Dehydrogenase; Nijmegen Rating = Classifications according to the Nijmegen criteria – Definite = score of 8-12, Probable = score of 5-7, Possible = score of 2-4; Mode = Mode of inheritance; Mat = Maternal inheritance; Spo = Sporadic inheritance; WGS Plasmy = Level of heteroplasmy from whole genome sequencing analysis; Pyroseq plasmy = Level of heteroplasmy from pyrosequencing analysis; ND = Not Determined. * = Not included in diagnostic analysis due to autopsy muscle being used and not blood. Note that some phenotypic features are relatively common and may not be directly related to mitochondrial disease (e.g. migraine).

eTable 5: Clinical details of patients with CPEO that had mitochondrial DNA deletions previously identified in urine or muscle that were not detectable using whole genome sequencing on blood DNA

ID	Age	Sex	Family History	Clinical features	Nijmegen rating	Muscle biopsy	Changes on muscle biopsy	Mitochondrial DNA deletion (tissue previously identified in)
B34	36	F	N	CPEO, myopathy	Probable	Y	Y	Single deletion (U)
E50	78	M	N	CPEO, myopathy	Possible	Y	Y	Single deletion (M)
E62	46	F	Y	CPEO, myopathy, COX negative and RRFs on muscle biopsy	Probable	Y	Y	Single deletion (M)
E63	38	M	N	CPEO, COX negative and SDH positive fibers on muscle biopsy	Probable	Y	Y	Single deletion (M)
B9	54	F	N	KSS, mitochondrial myopathy, SDH positive fibers on muscle biopsy	Definite	Y	Y	Single deletion (M)
B13	71	M	Y	CPEO, myopathy, cardiac arrhythmia, COX negative and RRFs on muscle biopsy	Definite	Y	Y	Single deletion (M)
A9	55	F	N	CPEO, myopathy, COX negative fibers on muscle biopsy	Definite	Y	Y	Multiple deletions (M)

ID = Patient identification number for this study; F = Female; M = Male; Y = Yes; N = No; COX = Cytochrome Oxidase; CPEO = Chronic Progressive External Ophthalmoplegia; KSS = Kearns-Sayre Syndrome; RRF = Ragged Red Fibers; SDH = Succinate Dehydrogenase; Nijmegen Rating = Classifications according to the Nijmegen criteria – Definite = score of 8-12, Probable = score of 5-7, Possible = score of 2-4; Tissue deletion previously detected in: M = muscle, U = urine.

SUPPLEMNTARY REFERENCES

- e1. Smith EH, Gavrilov DK, Oglesbee D, Freeman WD, Vavra MW, Matern D, Tortorelli S. An adult onset case of alpha-methyl-acyl-CoA racemase deficiency. *J Inherit Metab Dis.* **33**, S349S353 (2010).
- e2. Sawyer SL, Cheuk-Him Ng A, Innes AM, Wagner JD, Dyment DA, Tetreault M, Care4Rare Canada Consortium; Majewski J, Boycott KM, Screamton RA, Nicholson G. Homozygous mutations in MFN2 cause multiple symmetric lipomatosis associated with neuropathy. *Hum Mol Genet.* **24**, 51095114 (2015).
- e3. Tzoulis C, Papingji M, Fiskestrand T, Roste LS, Bindoff LA. Mitochondrial DNA depletion in progressive external ophthalmoplegia caused by POLG1 mutations. *Acta Neurol Scand Suppl.* **120**, 3841 (2009).
- e4. Burusnukul P, de los Reyes EC. Phenotypic variations in 3 children with POLG1 mutations. *J Child Neurol.* **24**, 482486 (2009).
- e5. Neeve VC, Samuels DC, Bindoff LA, van den Bosch B, Van Goethem G, Smeets H, Lombès A, Jardel C, Hirano M, Dimauro S, De Vries M, Smeitink J, Smits BW, de Coo IF, Saft C, Klopstock T, Keiling BC, Czermin B, Abicht A, Lochmüller H, Hudson G, Gorman GG, Turnbull DM, Taylor RW, Holinski-Feder E, Chinnery PF, Horvath R. What is influencing the phenotype of the common homozygous polymerase-gamma mutation p.Ala467Thr? *Brain.* **135**, 36143626 (2012).
- e6. Kasiviswanathan R, Longley MJ, Chan SS, Copeland WC. Disease mutations in the human mitochondrial DNA polymerase thumb subdomain impart severe defects in mitochondrial DNA replication. *J Biol Chem.* **284**, 19501-19510 (2009).
- e7. Woodbridge P, Liang C, Davis RL, Vandebona H, Sue CM. POLG mutations in Australian patients with mitochondrial disease. *Intern Med J.* **43**, 150156 (2013).
- e8. Luoma P, Melberg A, Rinne JO, Kaukonen JA, Nupponen NN, Chalmers RM, Oldfors A, Rautakorpi I, Peltonen L, Majamaa K, Somer H, Suomalainen A. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. *Lancet.* **364**, 875882 (2004).
- e9. Rajakulendran S, Pitceathly RD, Taanman JW, Costello H, Sweeney MG, Woodward CE, Jaunmuktane Z, Holton JL, Jacques TS, Harding BN, Fratter C, Hanna MG, Rahman S. A Clinical, Neuropathological and Genetic Study of Homozygous A467T POLG-Related Mitochondrial Disease. *PLoS One.* **11**, e0145500 (2016).
- e10. Nesbitt V, Alston CL, Blakely EL, Fratter C, Feeney CL, Poulton J, Brown GK, Turnbull DM, Taylor RW, McFarland R. A national perspective on prenatal testing for mitochondrial disease. *Eur J Hum Genet.* **22**, 1255-1259 (2014).

- e11. Bortot B, Barbi E, Biffi S, Lunazzi G, Bussani R, Burlina A, Norbedo S, Ventura A, Carrozzi M, Severini GM. Two novel POLG mutations causing hepatic mitochondrial DNA depletion with recurrent hypoketotic hypoglycaemia and fatal liver dysfunction. *Dig Liver Dis.* **41**, 494499 (2009).
- e12. Kurt B, Jaeken J, Van Hove J, Lagae L, Löfgren A, Everman DB, Jayakar P, Naini A, Wierenga KJ, Van Goethem G, Copeland WC, DiMauro S. A novel POLG gene mutation in 4 children with Alpers-like hepatocerebral syndromes. *Arch Neurol.* **67**, 239244 (2010).
- e13. Wong LJ, Naviaux RK, Brunetti-Pierri N, Zhang Q, Schmitt ES, Truong C, Milone M, Cohen BH, Wical B, Ganesh J, Basinger AA, Burton BK, Swoboda K, Gilbert DL, Vanderver A, Saneto RP, Maranda B, Arnold G, Abdenur JE, Waters PJ, Copeland WC. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. *Hum Mutat.* **29**, E150E172 (2008).
- e14. Needham M, Duley J, Hammond S, Herkes GK, Hirano M, Sue CM. Mitochondrial disease mimicking Charcot-Marie Tooth disease. *BMJ Case Rep.* **78**, 99100 (2007).
- e15. Garone C, Tadesse S, Hirano M. Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy. *Brain.* **134**, 33263332 (2011).
- e16. Hardy C, Khanim F, Torres R, Scott-Brown M, Seller A, Poulton J, Collier D, Kirk J, Polymeropoulos M, Latif F, Barrett T. Clinical and molecular genetic analysis of 19 Wolfram syndrome kindreds demonstrating a wide spectrum of mutations in WFS1. *Am J Hum Genet.* **65**, 12791290 (1999).
- e17. Shahni R, Wedatilake Y, Cleary MA, Lindley KJ, Sibson KR, Rahman S. A distinct mitochondrial myopathy, lactic acidosis and sideroblastic anemia (MLASA) phenotype associates with YARS2 mutations. *Am J Med Genet. A* **161A**, 23342338 (2013).
- e18. Negro R, Zoccolella S, Dell'aglio R, Amati A, Artuso L, Bisceglia L, Lavolpe V, Papa S, Serlenga L, Petruzzella V. Molecular analysis in a family presenting with a mild form of late-onset autosomal dominant chronic progressive external ophthalmoplegia. *Neuromuscul Disord.* **19**, 423426 (2009).
- e19. Virgilio R, Ronchi D, Hadjigeorgiou GM, Bordoni A, Saladino F, Moggio M, Adobbati L, Kafetsouli D, Tsironi E, Previtali S, Papadimitriou A, Bresolin N, Comi GP. Novel Twinkle (PEO1) gene mutations in mendelian progressive external ophthalmoplegia. *J Neurol.* **255**, 13841391 (2008).
- e20. Paradas C, Camano P, Otaegui D, Oz O, Emmanuele V, DiMauro S, Hirano M. Longitudinal clinical follow-up of a large family with the R357P Twinkle mutation. *JAMA Neurol.* **70**, 14251428 (2013).
- e21. Fratter C, Gorman GS, Stewart JD, Buddles M, Smith C, Evans J, Seller A, Poulton J, Roberts M, Hanna MG, Rahman S, Omer SE, Klopstock T, Schoser B, Kornblum C, Czernin B, Lecky B, Blakely EL, Craig K, Chinnery PF, Turnbull DM, Horvath R, Taylor RW. The clinical, histochemical, and molecular spectrum of PEO1 (Twinkle)-linked adPEO. *Neurology.* **74**, 16191626 (2010).

- e22. Lewis S, Hutchison W, Thyagarajan D, Dahl HH. Clinical and molecular features of adPEO due to mutations in the Twinkle gene. *J Neurol Sci.* **201**, 3944 (2002).
- e23. Hudson G, Deschauer M, Busse K, Zierz S, Chinnery PF. Sensory ataxic neuropathy due to a novel C10Orf2 mutation with probable germline mosaicism. *Neurology.* **64**, 371373 (2005).
- e24. Amati-Bonneau P, Guichet A, Olichon A, Chevrollier A, Viala F, Miot S, Ayuso C, Odent S, Arrouet C, Verny C, Calmels MN, Simard G, Belenguer P, Wang J, Puel JL, Hamel C, Malthièry Y, Bonneau D, Lenaers G, Reynier P. OPA1 R445H mutation in optic atrophy associated with sensorineural deafness. *Ann Neurol.* **58**, 958963 (2005).
- e25. Dadgar S, Hagens O, Dadgar SR, Haghigi EN, Schimpf S, Wissinger B, Garshasbi M. Structural model of the OPA1 GTPase domain may explain the molecular consequences of a novel mutation in a family with autosomal dominant optic atrophy. *Exp Eye Res.* **83**, 702706 (2006).
- e26. Yu-Wai-Man P, Shankar SP, Biousse V, Miller NR, Bean LJ, Coffee B, Hegde M, Newman NJ. Genetic screening for OPA1 and OPA3 mutations in patients with suspected inherited optic neuropathies. *Ophthalmology.* **118**, 558-563 (2011).
- e27. Ahmad KE, Davis RL, Sue CM. A novel OPA1 mutation causing variable age of onset autosomal dominant optic atrophy plus in an Australian family. *J Neurol.* **262**, 23232328 (2015).
- e28. Mukai M, Sugaya K, Matsubara S, Cai H, Yabe I, Sasaki H, Nakano I. [Familial progressive external ophthalmoplegia, parkinsonism and polyneuropathy associated with POLG1 mutation]. *Rinsho Shinkeigaku.* **54**, 417422 (2014).
- e29. Collet M, Assouline Z, Bonnet D, Rio M, Iserin F, Sidi D, Goldenberg A, Lardennois C, Metodiev MD, Haberberger B, Haack T, Munnich A, Prokisch H, Rötig A. High incidence and variable clinical outcome of cardiac hypertrophy due to ACAD9 mutations in childhood. *Eur J Hum Genet.* **24**, 11121116 (2016).
- e30. Milone M, Younge BR, Wang J, Zhang S, Wong LJ. Mitochondrial disorder with OPA1 mutation lacking optic atrophy. *Mitochondrion.* **9**, 279281 (2009).